Clinical Trial Update: Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease [Phase 2]

View source ↗

Summary

A Phase II trial update reports completion of a study evaluating the safety and efficacy of IdeS in Chronic Kidney Disease, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• IdeS (Immunoglobulin-degrading enzyme of Streptococcus pyogenes)

Snippet

Sponsor: Hansa Biopharma AB | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-05-23